Given our hypothesis that MUC1-mediated enhanced pancreatic cancer proliferation is mediated through SAT1, we treated MUC1-depleted cells with N1-acetylspermidine, the product of SAT1. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.